CORRECTING AND REPLACING Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a ...
15 May 2009 - 10:49AM
Business Wire
Eighth graph, third sentence should read: Fifty-five percent of
patients in the Tarceva arm and 64% of patients on placebo received
subsequent therapy after progressing.�(sted Sixty-four percent of
patients in the Tarceva arm and 55% of patients on placebo received
subsequent therapy after progressing.)
The corrected release reads:
DATA FROM THE PHASE III SATURN
STUDY SHOW TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL WHEN USED AS
A FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG
CANCER
-- Data Showed Tarceva Improved
PFS in Patients with Both Non-Squamous Cell Carcinoma and Squamous
Cell Carcinoma --
-- Patients with an EGFR Mutation
Achieved a 10 Fold Increase in the Time Patients Live Without Their
Disease Worsening �
-- Biomarker Data Suggest K-ras
Mutation Status is not a Predictor of Efficacy in NSCLC Patients
Treated with Tarceva --
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced detailed
results from the Phase III SATURN study of Tarceva� (erlotinib) as
a single agent, first-line maintenance therapy for patients with
advanced non-small cell lung cancer (NSCLC) who did not progress
following first-line treatment with platinum-based chemotherapy.
The study met both of its co-primary endpoints by demonstrating a
statistically significant 41% improvement in the time patients live
without their disease worsening (as measured by progression free
survival, or PFS) compared with placebo (Hazard Ratio = 0.71,
p-value
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More OSI Pharmaceuticals, Inc. News Articles